TY - JOUR T1 - Symptoms and risk factors for hospitalization of COVID-19 presented in primary care JF - medRxiv DO - 10.1101/2021.03.26.21254331 SP - 2021.03.26.21254331 AU - S Rabady AU - K Hoffmann AU - M Brose AU - O Lammel AU - S Poggenburg AU - M Redlberger-Fritz AU - K Stiasny AU - M Wendler AU - L Weseslindtner AU - S Zehetmayer AU - G Kamenski Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/26/2021.03.26.21254331.abstract N2 - Background Little is known about early symptoms and symptom development in mild to moderate Covid-19 disease, and about their prognostic value. This applies for health professionals as well as for decision makers and lays but has significant impact on testing strategies and early detection. Few data have been collected in primary care so far.Aim It was the aim of this study to extend knowledge of early symptoms as a precondition of early identification, and to gain understanding of associations between symptoms and severe courses of the disease.Design and Settings This study was designed as a retrospective observational study in Austrian GP practices in the year 2020.Methods Patients above 18 years with a positive SARS-CoV-2 test were included.Data collection comprised basic demographic data, risk factors and the recording of symptoms at several points in time in the course of the illness.Results Little more than one third of patients report symptoms generally understood to be typical for Covid-1. Most patients present with a variety of unspecific complaints. We found symptoms indicating complicated disease if present at certain points in time. The number of symptoms is likely to be a predictor for the need of hospital care. More than 50% of patients experience symptoms after 14 days.Conclusions Underrating unspecific symptoms as possible indicators for SARS-CoV-2 infection harbours the danger of overlooking early disease. Monitoring patients during their illness using certain indicators for severe disease may help to identify patients who are likely to profit from early intervention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00022448Funding StatementNone of the authors received any payments or services from a third party for any aspect oft the submitted work. The department for general medicine, Karl Landsteiner Universitaet received a grant of Euro 500 by the Styrian Academy of Family Medicine, Graz, AustriaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the Commission for Scientific Integrity and Ethics, Karl-Landsteiner Private University for Health Sciences, Krems, Austria. Votum Nr: 1046/2020 13/07/20 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available from: Department of General Medicine and Family Practice, Karl Landsteiner Privatuniversitaet, Krems, Austria ER -